Array biopharma to present at the stifel nicolaus healthcare, newsmakers in the biotech industry and morgan stanley global healthcare conferences

Boulder, colo.--(business wire)--array biopharma inc. (nasdaq: arry) today announced that its chief executive officer, ron squarer, will speak at the following upcoming conferences. the public is welcome to participate in the conferences through webcasts on the array biopharma website: www.arraybiopharma.com. event: date: time: location: event: date: time: location: event: date: time: location: grand hyatt, new york, ny about array biopharma array biopharma inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small-molecule drugs to treat patients afflicted with cancer. array is evolving into a late-stage development company, with two wholly-owned programs, arry-614 and arry-520, and three partnered programs, selumetinib partnered with astrazeneca, mek162 partnered with novartis, and danoprevir, partnered with intermune / roche, having the potential to begin phase 3 or pivotal trials by the end of calendar year 2013. for more information on array, please go to www.arraybiopharma.com.
ARRY Ratings Summary
ARRY Quant Ranking